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Signalling pathways activated by glucagon-like  
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role in protection against ischaemia 
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Summary
Glucagon-like	 peptide-1	 is	 an	 incretin	 hormone	 proposed	
to	have	insulinomimetic	effects	on	peripheral	insulin-sensi-
tive	tissue.	We	examined	these	effects	on	the	heart	by	using	
isolated,	perfused	rat	hearts	and	adult	ventricular	myocytes.	
During	normoxic	perfusion,	no	effects	of	escalating	concen-
trations	 of	 GLP-1	 on	 either	 heart	 rate	 or	 left	 ventricular	
developed	 pressure	 were	 found.	With	 functional	 perform-
ance	as	readout,	we	found	that	GLP-1	directly	protected	the	
heart	against	damage	incurred	by	global	low-flow	ischaemia.	
This	protection	was	sensitive	to	the	presence	of	iodo-acetate,	
implicating	 activation	 of	 glycolysis,	 and	 was	 abolished	 by	
wortmannin,	indicative	of	Pi-3-kinase	as	mediator	of	protec-
tion.	in	addition,	GLP-1	had	an	infarct-sparing	effect	when	
supported	 by	 the	 presence	 of	 the	 dipeptidyl	 peptidase-iv	
inhibitor	valine	pyrrolidide.	
GLP-1	could	not	directly	activate	protein	kinase	B	(also	
called	Akt)	or	the	extracellular	regulated	kinases	Erk1/2	in	
hearts	or	cardiocytes	under	normoxic	conditions,	but	phos-
phorylation	of	the	AMP-activated	kinase	(AMPK)	on	Thr172	
was	 enhanced.	 in	 addition,	 the	 glycolytic	 enzyme	 phos-
phofructokinase-2	was	activated	dose	dependently.	During	
reperfusion	after	 ischaemia,	modulation	of	 the	phosphory-
lation	 of	PKB/Akt	 as	well	 as	AMPK	was	 evident.	GLP-1	
therefore	directly	protected	the	heart	against	low-flow	isch-
aemia	by	 enhancing	glycolysis,	 probably	 via	 activation	of	
AMP	kinase	and	by	modulating	the	profile	of	activation	of	
the	survival	kinase	PKB/Akt.
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Glucagon-like peptide-1 (GLP-1) is an incretin hormone secret-
ed rapidly from the intestine in response to nutrient ingestion.1 
The plasma levels of this hormone are tightly regulated by the 
enzyme dipeptidyl peptidase IV.2 
GLP-1 plays a role in regulating plasma glucose levels by 
enhancing insulin secretion from the pancreatic beta-cells3 in 
conjunction with diminishing levels of glucagon and somato-
statin. Insulin release is mediated via activation of a specific 
GLP-1 receptor that is linked to activation of adenylyl cyclase 
and a subsequent rise in cAMP and activation of PKA. These 
signalling events effect a rise in intracellular Ca21 as trigger for 
insulin secretion through closure of the KATP channels. GLP-1 
has turned out to be the most potent and efficient regulatory 
stimulator of insulin secretion discovered thus far. Clinical stud-
ies investigating type 2 diabetes revealed that GLP-1 is strongly 
insulinotrophic, even in patients with long-standing illness and 
secondary sulphonylurea failure.4 
Recent evidence suggests also that GLP-1 has peripheral 
effects to enhance glucose utilisation in insulin-sensitive tissues 
(ie, fat, muscle and liver).5,6 It stimulates glycogen synthesis and 
increases glycolysis and glucose oxidation in the liver,7 isolated 
rat soleus muscle8 and adipocytes,9 as well as in human skeletal 
muscle.10 Specific receptors for GLP-1 have been described in 
adipocytes,11 lung tissue,12 liver13 and gastric mucosa14 while 
northern blot analysis revealed the presence of mRNA for 
the receptor protein in diverse tissues, including the heart.15,16 
Cloning and sequencing of the heart isoform furthermore 
revealed the same deduced amino acid sequence as the pancre-
atic receptor.16 However, analysis of the provoked signalling 
of GLP-1 binding to peripheral tissue17,18 or cells transfected 
with receptor protein17 argues for a different response than 
the cAMP−PKA pathway evoked in beta-cells, pointing to the 
possible activation of multiple signalling pathways. 
GLP-1 infusion in rats resulted in myocardial pressor 
effects19,20 while infusion in humans after acute myocardial 
infarction afforded improved left ventricular function.21 Therapy 
for type 2 diabetics based on the actions of GLP-1 is hailed as 
one of the most promising recent approaches to this disease. In 
view of the vulnerability of the heart in type 2 diabetes and the 
documented effects of GLP-1 on pancreatic as well as periph-
eral tissue, we aimed to investigate the myocardial effects of 
GLP-1 using isolated, perfused rat hearts and adult ventricular 
myocytes.
Materials and methods
Male Wistar rats (225−250 g) were used in this study. The 
animals had free access to food and water and were kept on a 
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12-hour day/night cycle in an AAALAC-accredited facility. Rats 
were anaesthetised by intraperitoneal injection of sodium pento-
barbital (160 mg/kg). The study conformed to the Guide for the 
Care and Use of Laboratory Animals of the NIH (Publication 
No. 85-23, revised 1996). 
GLP-1 (7-36) amide (Sigma) was used in this study and is 
henceforth indicated as GLP-1. Wortmannin, glucose-6-phos-
phate, fructose-6-phosphate, pyrophosphate-sensitive PFK and 
pyrophosphate reagent were from Sigma, collagenase type 2 
was from Worthington, bovine serum albumin (BSA) (fraction 
V, fatty acid free) from Boehringer Mannheim and all antibodies 
from Cell Signaling. The DPP-IV inhibitor, valine pyrrolidide, 
was kindly supplied by Novo Nordisk, Denmark. All other 
chemicals were of the highest grade commercially available.
isolated	heart	perfusions
After anaesthesia, the hearts were quickly excised and arrested 
in ice-cold Krebs–Henseleit solution (KR) and perfused retro-
gradely.22 They were fitted with an intraventricular balloon to 
monitor left ventricular pressure. 
The myocardial temperature and left ventricular developed 
pressure (LVDevP) were monitored throughout the experiment 
as reported previously.22 Global low-flow ischaemia was induced 
by reducing the coronary flow rate from 11.4 ± 0.4 ml/min to 
0.2 ml/min, by means of a Gilson Minipuls 2 peristaltic pump. 
The hearts were perfused according to the protocol indicated 
and described in Fig. 1, freeze-clamped at the times indicated 
and stored in liquid nitrogen for biochemical analyses. 
infarct	size	determination
The infarct size after regional ischaemia was determined after 
coronary artery ligation for 35 min, followed by reperfusion for 
30 min as described previously,22,23 and expressed as a percent-
age of the area at risk. 
Preparation	of	myocytes
Calcium-resistant adult ventricular myocytes in an unstimulated 
state were prepared as described previously.24 After isolation, 
the myocytes were suspended in a buffer containing, in mmol/l: 
HEPES, 10; KCl, 6; NaH2PO4, 0.2; Na2HPO4, 1; MgSO4, 1.4; 
NaCl, 128; pyruvate, 2; glucose, 5.5; 2% BSA (fraction V, fatty 
acid free) plus 1.25 mmol/l calcium, pH 7.4. The cells were left 
for one to two hours under an oxygen atmosphere on a gently 
shaking platform to recover from the trauma of isolation. This 
procedure routinely rendered in excess of 80% viable cells as 
measured by trypan blue exclusion.
After recovery, the cells were spun down into a loose pellet 
(3 min at 100 rpm), and washed twice with and suspended in a 
suitable volume of the above medium from which pyruvate was 
omitted (buffer A). 
Cyclic	AMP	determination
For tissue cyclic AMP analysis, 100−200 mg of frozen tissue 
was extracted with 1.2 ml 6% perchloric acid. Extracts were 
neutralised and cAMP content was determined using a commer-
cial kit (Amersham) according to the manufacturer’s instruc-
tions. A standard curve ranging from 0.125−16 pmol cAMP was 
included in each assay.
immunoblotting	for	determination	of		
phosphorylated	kinases
Frozen tissue was lysed (polytron PT-10 homogeniser; 2 × 4 sec, 
setting 4) and myocytes were sonicated on ice in buffer contain-
ing, in mmol/l: tris-HCl, 20 (pH 7.5); EGTA, 1; EDTA, 1; NaCl, 
150; Na2VO3, 1; beta-glycerophosphate, 1; sodium-pyrophos-
phate, 2.5; PMSF, 0.3; Triton X-100 1% (v/v) plus 10 µg/ml 
leupeptin and aprotinin, respectively. Lysates were cleared from 
particulate matter by spinning for 15 min at 14 000 rpm in a 
microfuge. Equal amounts of cytosolic proteins25 were separated 
on a 10% SDS poly-acrylamide gel and electro-transferred to 
ImmobilonTM-P membranes. 
The membranes were blocked for two hours in tris-buff-
ered saline (TBS) containing 0.1% Tween-20 and 5% non-fat 
a: control 5 60 min perfusion
b: 30 min perfusion with GLP-1, 1021121028 mol/l
c: low-flow ischaemia
d: pharmacological manipulation of ischaemic events
e: time points of phosphoprotein determination
30 min
VP ± GLP-1
5 min 40 min, 0.2 ml/min
VP ± GLP-1
25 min 30 min
40 min
Wortmannin/ 
Iodo-acetate
30 min 30 min
40 min30 min 5 min 15 min 30 min
Stabilisation
30 min
Stabilisation Ischaemia Reperfusion
Stabilisation Ischaemia Reperfusion
Stabilisation Ischaemia Reperfusion
Fig. 1. Perfusion protocol of hearts subjected to 
Langendorff perfusion as described in the text, with hori-
zontal arrows indicating the presence of the indicated 
substances. (a) 60-min control perfusion; (b) 30-min 
stabilisation followed by 30-min stimulation with differ-
ent concentrations of GLP-1 ± 20 µmol/l VP; (c) 30-min 
stabilisation followed by 40-min low-flow ischaemia and 
30-min reperfusion. GLP-1 ± VP was started 5 min after 
the onset of perfusion; (d) 100 nmol/l wortmannin or 75 
µmol/l iodo-acetate were added at the onset of ischae-
mia; (e) hearts were freeze-clamped as indicated by the 
arrows at the end of stabilisation (basal), after 5, 15 or 30 
min of reperfusion, for analyses of the phosphoprotein 
content. 
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milk powder, after which they were probed for 16 hours with 
a primary antibody (Ser473- or Thr308-phosphorylated PKB/Akt, 
total PKB/Akt, GSKα/β as downstream substrate of PKB/Akt, 
Thr172-phosphorylated AMP-activated protein kinase or Erk1/2). 
Quantification was done by laser scanning densitometry and 
suitable software (UN-SCAN-IT, Silkscience). Care was taken 
to include a reference standard on all blots for comparison 
purposes.
Determination	of	fructose-2,6-bisphosphate	levels
Cardiomyocytes in buffer A were stimulated with different 
concentrations of GLP-1 by incubation under an oxygen atmos-
phere in a shaking water bath at 37°C for 30 min, where after the 
cells were loosely spun down, the supernatant was aspirated and 
the pellet washed twice with buffer A. Cells were lysed by soni-
cating on ice in the following buffer, in mmol/l: HEPES, 20 (pH 
7.5); NaF, 20; KCl, 30; EDTA, 5; EGTA, 5; Na2VO3, 1; DTT, 1; 
benzamidine, 1; leupeptin, 4 µg/ml; and aprotinin, 1 µg/ml. The 
protein concentrations were determined,25 and lysate containing 
equal amounts of protein were mixed with an equal volume of 
0.1 N NaOH and incubated for 5 min at 80°C.26 At this point, 
samples were stored at −80°C until assayed. 
The lysates were then microfuged (10 min at 14 000 rpm 
at 4°C) and neutralised with 0.1 N CH3COOH. After neutrali-
sation, the samples were centrifuged as above. Twenty-five 
microlitres of the supernatant was assayed for fructose-2,6-
bisphosphate (fru-2,6-P2) content using its ability to stimulate 
PFK-1 in a coupled enzyme system containing 0.5 mmol/l 
pyrophosphate, pyrophosphate-sensitive fructose-6-phosphate 
kinase from potato tubers and a commercial pyrophosphate 
reagent cocktail. In this reaction, β-NADH is oxidised to NAD, 
which can be followed spectrophotometrically at A340 nm. The 
reaction was performed in a Beckman DU640 temperature-
controlled spectrophotometer coupled to a PC with suitable 
software. Readings were taken at 20-sec intervals over a 3-min 
period and the rate of formation calculated as ΔA340 nm/20 sec.
Statistical	analyses
Data are presented as mean ± SEM. Comparisons between 
multiple groups were performed by one-way ANOVA, two-
way ANOVA or repeated-measures ANOVA, followed by the 
Bonferroni post-hoc test (Graph-Pad Prism). A value of p < 0.05 
was considered statistically significant. 
Results
Over a 30-min period, escalating concentrations of GLP-1 
(10211–1028 mol/l) in the presence of 20 µmol/l valine pyrro-
lidide (VP) had no effect on either heart rate or left ventricular 
developed pressure (results not shown). In addition, there was 
no evidence of accumulation of cAMP in the tissue under these 
conditions (360.7 ± 11.1 control vs 373 ± 20.5 pmol/g ww).
Isolated hearts were subjected to 40 min of normothermic 
low-flow (0.2 ml/min) ischaemia in the presence or absence of 
10210 mol/l GLP-1 and 20 µmol/l VP (Fig. 1c). The presence of 
GLP-1 resulted in a significantly improved rate pressure product 
(RPP) recovery on reperfusion (55.64 ± 6.83% of pre-ischaemic 
values vs 29.75 ± 4.97% without GLP-1) (Fig. 2a). Addition of 
the PI-3-kinase inhibitor wortmannin (100 nmol/l) before the 
onset of ischaemia abolished this protective effect (Fig. 2a). 
Similarly, the presence of 75 µmol/l iodo-acetate during the 
ischaemic period abolished protection while having no effect 
Fig. 2. The presence of 10210 mol/l GLP-1 protected hearts from the damage incurred by a 40-min period of low-flow 
ischaemia (Figs 1c, d). (a) 100 nmol/l wortmannin; (b) 75 µmol/l iodo-acetate, added 5 min before the onset of ischae-
mia (Fig. 1d), abolished this protection, in both instances having no effect on the performance of control hearts. **p 
< 0.01, ***p < 0.001 (n 5 six to eight hearts per group).
Fig. 3. Hearts were subjected to 35-min regional ischae-
mia by coronary artery ligation in the presence of 10210 
mol/l GLP-1, with or without 20 µmol/l VP as indicated, 
and infarct size was determined as a percentage of the 
area at risk. **p < 0.01 (n 5 six to 11 hearts per group). 
(a) (b)
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Fig. 4. Lysates were prepared from hearts perfused with GLP-1 (10210–1028 mol/l) as indicated in Fig. 1b, with insulin 
stimulation (10 min at 100 nmol/l) as positive control. Equal amounts of protein were subjected to SDS-PAGE and 
electro-transferred to PVDF membranes. The membranes were probed with antibodies against (a) the serine- or 
threonine-phosphorylated forms of PKB/Akt, total Akt protein and GSKα/β; or (b) phospho-ERK1/2. Representative 
blots are given. At least four hearts were analysed per concentration point.
Fig. 5. Isolated cardiomyocytes were stimulated with GLP-1, as indicated, after which they were lysed as described 
in Methods. (a) Cells were pre-treated with either 100 nmol/l wortmannin or 5 nmol/l exendin 9-39 for 10 min, before 
stimulation with10210 mol/l GLP-1 for 30 min. Immunoblots were probed with anti-Thr172 AMP kinase Ab. **p < 0.01, 
***p < 0.001 (n 5 six to eight hearts per group). (b) The lysates were treated to protect the fru-2,6-P2 formed. Fru-2,6-
P2 content was then assayed using its ability to stimulate the activity of the pyrophosphate-sensitive PFK enzyme 
from potato tubers. A representative experiment is shown and was repeated three times in duplicate, with similar 
results.
(a) (b)
(a)
(b)
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on the post-ischaemic performance of hearts perfused without 
GLP-1 (Fig. 2b). 
As shown in Fig. 3, 10210 mmol/l GLP-1, in the presence 
of the DPP-IV inhibitor VP (20 µmol/l), significantly reduced 
infarct size in comparison to control hearts, when expressed as 
a percentage of the area at risk. The presence of VP did not alter 
the infarct size of control hearts. The area at risk was similar 
in control vs treated hearts (56.02 ± 2.25 vs 54.13 ± 2.21%, 
n 5 6).
Signalling	pathways	involved	in	GLP-1	actions
The results presented in Fig. 2a show that the protection afforded 
by GLP-1 against ischaemic damage involved the well-known 
pro-survival kinase PI-3-kinase. However, in hearts perfused 
for 30 min under normoxic conditions with GLP-1 (10211–1028 
mol/l) (Fig. 1e), no evidence of phosphorylation of PKB/Akt 
or GSKα/β as downstream substrates of this pathway could be 
found (Fig. 4a). Similarly, in the cardiomyocytes, there was no 
evidence of phosphorylation of these proteins after stimulation 
with the same concentrations of GLP-1 (results not shown). The 
extracellular regulated kinase Erk1/2 was also not activated in 
hearts or myocytes stimulated under these conditions (Fig. 4b). 
Under normoxic perfusion conditions, therefore before the 
onset of ischaemia, as low as 10211 mmol/l GLP-1 resulted in a 
significant phosphorylation of AMP-activated kinase on Thr172 
(Figs 5a, 6b). In cardiomyocytes, this effect could be abolished 
by the presence of 5 nmol/l exendin 9-39, a specific antagonist of 
GLP-1, but not by wortmannin (Fig. 5a). Furthermore, as shown 
in Fig. 5b, dose-dependent activation of the enzyme phosphof-
ructokinase-2 occurred, as measured by accumulation of fru-2,6-
P2 and the ability of the latter to stimulate the activity of PFK-1. 
To understand the involvement of the PI-3K, PKB/Akt or the 
AMPK signalling pathways in the protective effects of GLP-1 
against ischaemia, we documented the profile of the phospho-
rylation state of these kinases during low-flow ischaemia and 
the reperfusion phases. Contrary to expectation, the presence of 
GLP-1 had no effect on the activation of PKB/Akt during the 
ischaemic phase and attenuated its activation during reperfusion 
(Fig. 6a). Although activation of PKB/Akt was always lower in 
the presence of GLP-1 during reperfusion, the temporal pattern 
of activation was similar to the hearts perfused in the absence of 
GLP-1, declining during ischaemia, with a significant peak of 
activation after 15 min reperfusion, and again declining towards 
30 min reperfusion. 
AMPK, as expected, showed strong activation during ischae-
mia that increased with time. Again the presence of GLP-1 did 
not alter this. However, during reperfusion, in contrast to the 
lower PKB/Akt activation compared to control hearts, observed 
in the presence of 10210 mol/l GLP-1, Thr172 phosphorylation 
of AMPK was consistently enhanced above control values. We 
furthermore observed a peak of activation of this kinase at 15 
min reperfusion (Fig. 6b). 
Discussion
GLP-1 or substances such as the DPP-IV inhibitor valine 
pyrrolidide, which probably act via GLP-1,27 are currently hot 
topics of attention as possible antidiabetic agents. Some of 
these substances have already passed phase 3 clinical trials and 
are used in practice. Recently published data show that GLP-1 
promotes peripheral glucose utilisation5,6 but, more importantly, 
Nikolaidis et al.21 reported that infusion of GLP-1 as added 
therapy gave additional benefit to patients with acute myocar-
dial infarction and severe systolic dysfunction after primary 
angioplasty. Because of the latter, this study set out to investi-
gate the effects of GLP-1 on the isolated, perfused rat heart in 
conjunction with adult ventricular myocytes. 
During normoxic perfusion conditions, we found no direct 
effect of GLP-1 (10211–1028 mol/l) in the presence of VP on 
either heart rate or left ventricular developed pressure (results 
not shown). This supports the conclusion of previous studies 
that myocardial pressor effects of GLP-1 are solely of auto-
nomic origin.19,20 The DPP-IV inhibitor valine pyrrolidide did 
not alter any of the measured parameters and all control hearts 
were therefore perfused in the presence of 20 µmol/l VP. 
Using the isolated, perfused heart, we demonstrated that the 
presence of 10210 mol/l GLP-1, besides having an infarct-sparing 
effect, afforded protection against global low-flow ischaemia, as 
measured by the RPP as an index of functional recovery. This 
improved recovery was because of enhanced glycolysis, since 
the presence of iodo-acetate abolished the protection. Moreover, 
our results indicated that the protective effects were mediated by 
PI-3-kinase, as reflected by inhibition of the protection afforded 
by wortmannin. During low-flow ischaemia, a model recog-
nised as more representative of what happens during infarction 
in vivo, oxidation of glycogen becomes an important energy 
source,28 underscoring the conclusion that this is a relevant part 
of the protective effects of GLP-1.
In spite of the above results, GLP-1 did not activate PKB/Akt 
as downstream substrate of PI-3-kinase, as evidenced by a lack 
of phosphorylation of this kinase on either Ser473 or Thr308 or of 
its substrate, GSK-3α/β, in myocytes or perfused hearts (Figs 
4a, b). This corroborates findings presented by Zhao et al.,29 
who also could not demonstrate phosphorylation of PKB/Akt 
after stimulation of hearts with GLP-1. According to our results, 
the presence of GLP-1 attenuated the phosphorylation of PKB/
Akt normally seen on reperfusion of a heart after an ischaemic 
period (Fig. 6a). These results therefore implicate a different 
downstream effector of PI-3-K to be involved as mediator of 
protection.
AMP-activated kinase also stimulates glycolysis in the heart 
by direct activation of PFK-2.30 As shown in Fig. 6b, GLP-1 
treatment resulted in enhanced phoshorylation of AMPK in 
normoxic, perfused hearts. In addition, in isolated cardiomyo-
cytes, GLP-1 stimulated activation of PFK-2, as evidenced by 
a rise in fru-2,6-P2 levels (Fig. 5b). These results may therefore 
also explain the protection against ischaemic damage observed 
in hearts perfused with GLP-1. 
It is well recognised that the effects of AMPK are not abol-
ished by wortmannin. Underscoring this, wortmannin could 
not abolish AMPK phosphorylation after GLP-1 treatment of 
cardiomyocytes, whereas the specific inhibitor, exendin 9-39 
could do so (Fig. 5a). In addition, exendin 9-39 attenuated basal 
levels of AMPK activation. This indicates that either the inhibi-
tor has effects independent of GLP-1 signalling, or that GLP-1 
tonically regulates AMPK activation in cardiomyocytes. 
Opposite to the effects noted on PKB/Akt activation, AMPK 
was consistently in a higher phosphorylated state during the 
reperfusion phase after ischaemia in the presence of GLP-1, 
with strong activation noted at 15 min reperfusion. The effects 
of GLP-1 on PKB/Akt and AMPK phosphorylation may be a 
direct or indirect effect as cross talk between the two kinases has 
been described previously.31
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Although we found no evidence of cAMP accumulation in 
hearts perfused with GLP-1 under normoxic conditions, and our 
results for p42/44 ERK activation are not conclusive for activa-
tion of this kinase, the work of Bose et al.32 demonstrated a role 
for both in the actions of GLP-1 to protect against ischaemia. 
Raised cAMP is a well-documented occurrence during myocar-
dial ischaemia, while the above study showed that inhibition of 
activation of the p42/44 ERK abolished the protection afforded 
by GLP-1.32 Our results, in turn, argue that GLP-1 modulates the 
response of the heart to ischaemia/reperfusion with regard to the 
survival kinase profile activated, but does not directly activate 
these kinases. We could, however, inhibit ERK activation with 
the MEK inhibitor PD098059 in future, to clarify the role of 
ERK in the protection elicited by GLP-1. 
Fig. 6. Hearts were perfused with or without GLP-1, as indicated in Fig. 1c and freeze-clamped at the indicated 
time points (Fig. 1e) for analysis of the phosphoprotein content by western blotting, as described in Methods. 
Phosphorylation of (a) Ser473 on PKB/Akt; and (b) Thr172 on AMPK were measured. *p < 0.05, **p < 0.01 and ***p < 0.001 
vs basal levels within group. #p < 0.05 vs control. Four to eight individual hearts were analysed per time point. 
(a)
(b)
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Conclusion
This study showed that GLP-1 activated AMPK in the hearts and 
could protect the heart against low-flow ischaemia by enhancing 
glycolysis, but that PKB/Akt was probably not involved in this 
protection. Furthermore, the extent of phosphorylation of both 
PKB/Akt and AMPK on reperfusion was altered by the presence 
of GLP-1. GLP-1 therefore altered the response of the heart to 
an ischaemic incident. To the best of our knowledge, this is the 
first study indicating a role for AMP kinase activation in the 
actions of GLP-1 on the heart. 
We acknowledge the kind gift of the DPP-IV inhibitor, valine pyrrolidide, 
from Novo Nordisk, Denmark.
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